3,4-difluorobenzylidene curcumin

3,4-difluorobenzylidene curcumin (CDF) is a **novel fluorinated analogue of curcumin** developed to improve bioavailability and antitumor activity compared to curcumin itself. CDF demonstrates around **three times higher bioavailability** than curcumin and displays preferential accumulation in the pancreas, reaching tissue concentrations twice that of curcumin. As an antitumor agent, it possesses **stronger cytotoxic effects** against multiple cancer cell lines, including chemoresistant ones, and inhibits tumor growth through effects on cancer stem cell self-renewal, invasiveness, angiogenesis, and enhanced chemosensitivity. Mechanistically, CDF modulates diverse targets including several miRNAs (miR-21, miR-101, miR-210, miR-34a, miR-34c), PTEN, CD44, EGFR, EpCAM, EZH2, HIF-1α, and VEGF. CDF is under investigation primarily as a potential therapy for **pancreatic cancer** and other malignancies[1][5][6].

Other names

3,4-difluorobenzylidene curcuminCDF